8-K: Coherus Oncology Receives Nasdaq Delisting Notice for Sub-$1.00 Share Price

Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its common stock trading below the $1.00 minimum bid price requirement, initiating a 180-day compliance period.

Summary

• Coherus Oncology, Inc. received a deficiency notice from the Nasdaq Stock Market LLC on June 30, 2025.
• The notice indicates that the company's common stock bid price closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
• This notice does not immediately affect the listing of the company's common stock on the Nasdaq Global Market.
• The company has 180 calendar days, until December 29, 2025 (the Compliance Date), to regain compliance.
• To regain compliance, the common stock must maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date.
• If compliance is not achieved by the Compliance Date, the company may be eligible for an additional 180-calendar day period by transferring its listing to the Nasdaq Capital Market and meeting other applicable initial listing standards, excluding the bid price requirement.
• To qualify for a second compliance period, the company would need to provide written notice to Nasdaq of its intention to cure the deficiency, potentially by effecting a reverse stock split.
• The company intends to actively monitor its common stock's closing bid price and evaluate available options to resolve the deficiency and regain compliance.

Sentiment

Score: 3

Explanation: The company received a deficiency notice from Nasdaq for failing to meet the minimum bid price requirement, indicating a negative market perception and potential future challenges, though a compliance period is granted.

Negatives

• Received a deficiency notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement.
• The company's stock has traded below $1.00 for 30 consecutive business days, indicating sustained low market valuation.
• Risk of potential delisting from the Nasdaq Global Market if compliance is not regained.

Risks

• Potential delisting of common stock from the Nasdaq Global Market if the minimum bid price requirement is not met by December 29, 2025.
• Inability to qualify for an additional 180-day compliance period if the company does not meet the criteria for transfer to the Nasdaq Capital Market or if Nasdaq Staff determines the deficiency cannot be cured.
• Failure of any appeal to a Nasdaq hearings panel if a delisting notice is issued.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and evaluate available options to resolve the deficiency and regain compliance with the Nasdaq minimum bid price requirement.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the Nasdaq minimum bid price requirement.

Industry Context

Receiving a Nasdaq deficiency notice for a sub-$1.00 bid price is a common challenge for smaller biotechnology and pharmaceutical companies, often reflecting investor concerns about pipeline progress, market competition, or overall financial health. It can signal a period of increased scrutiny and pressure on management to demonstrate value and stability.

Comparison to Industry Standards

• The Nasdaq Listing Rule 5450(a)(1) requiring a minimum $1.00 bid price is a standard for continued listing on the Nasdaq Global Market, applicable to all listed companies.
• Many companies, particularly in the volatile biotech sector, periodically face similar compliance issues, with some successfully regaining compliance through operational improvements, positive clinical data, or corporate actions like reverse stock splits, while others may ultimately delist.

Stakeholder Impact

• Shareholders face increased uncertainty regarding the company's stock value and the risk of delisting, which could impact liquidity and investment value.
• Employees may face concerns about the company's stability and future prospects.

Next Steps

• Monitor the closing bid price of common stock.
• Evaluate available options to resolve the bid price deficiency.
• Potentially effect a reverse stock split if necessary to regain compliance.
• If non-compliant by December 29, 2025, potentially transfer listing to the Nasdaq Capital Market to qualify for an additional compliance period.
• Prepare for potential appeal to a Nasdaq hearings panel if a delisting notice is received.

Key Dates

Recommendation

Keywords

Coherus Oncology, CHRS, Nasdaq, delisting, bid price, compliance, deficiency notice, stock market, biotechnology, pharmaceuticals